Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252291 · ClinicalTrials.gov registry record · Phase 3
Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics
A Phase 3 study of Asthma, sponsored by Syntara.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT00252291 is a Phase 3 study of Asthma that has completed, run by Syntara. The registered enrollment target is 240 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00252291, a Phase 3 study of Asthma, has completed, sponsored by Syntara.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 \>70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.
Conditions Studied
Interventions
- DRUG Aridol
- DRUG Methacholine
- PROCEDURE Exercise challenge
Study Locations (1)
Colorado
- Colorado Asthma and Allergy Centers, 125 Rampart Way - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252291
The ClinicalTrials.gov registry entry for NCT00252291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The listed sponsor is Syntara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Aridol is the first listed.
NCT00252291 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00252291 about?
NCT00252291 is a clinical study titled "Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics". This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function...
What is the current status of trial NCT00252291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2005-11. Estimated completion is 2006-09.
What conditions does trial NCT00252291 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00252291?
The interventions under investigation include: Aridol (DRUG), Methacholine (DRUG), Exercise challenge (PROCEDURE).
Who is sponsoring clinical trial NCT00252291?
This trial is sponsored by Syntara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00252291 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.